uploads/2018/05/Eylea.png

How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?

By

Updated

Eylea revenue trends

In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17, which reflected a ~20% rise on a YoY (year-over-year) basis.

Regeneron Pharmaceuticals (REGN) and Bayer (BAYZF) commercialize Eylea both in and outside of the US market, respectively. Regeneron reported revenue of $984 million from sales of Eylea in the US market, which reflected ~15% YoY growth and ~1% growth quarter-over-quarter. Bayer reported revenue of $624 million from sales of Eylea outside the US market.

Article continues below advertisement

In March, Regeneron announced positive results from its PANORAMA trial, which evaluated the safety and efficacy of the Eylea injection for the treatment of moderate to severe non-proliferative diabetic retinopathy. Regeneron plans to submit a supplemental Biologics License Application (or sBLA) to the FDA by the end of 2018.

The label expansion of Eylea is expected to further boost the drug’s revenue growth.

Kevzara and Zaltrap revenue trends

In 1Q18, Regeneron Pharmaceuticals’ Kevzara reported revenue of $12 million compared to $3 million and $9 million in 3Q17 and 4Q17, respectively.

In the rheumatoid arthritis drugs market, Kevzara faces stiff competition from AbbVie’s (ABBV) Humira, Bristol-Myers Squibb’s (BMY) Orencia, Amgen’s (AMGN) Enbrel, Roche’s (RHHBY) Rituxan, and Johnson & Johnson’s (JNJ) Simponi. In the crowded segment of biologics for rheumatoid arthritis, Kevzara still holds a differentiated product profile, and Regeneron Pharmaceuticals expects steady growth in 2018. Regeneron is working with payers to secure improved access to Kevzara.

In 1Q18, Zaltrap reported revenue of $26 million compared to $21.7 million and $25 million in 3Q17 and 4Q17, respectively. Zaltrap is indicated in combination with FOLFIRI (5-fluorouracil, leucovorin, irinotecan) for the treatment of individuals with metastatic colorectal cancer that is resistant or progressed after an oxaliplatin-containing regimen.

Advertisement

More From Market Realist